Loading...

Brilliant Violet 421™ anti-human CD197 (CCR7) Antibody

Pricing & Availability
Clone
G043H7 (See other available formats)
Regulatory Status
RUO
Other Names
BLR2, CDw197, EBI1, CMKBR7
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
G043H7_BV421_1_101111
Human peripheral blood lymphocytes were stained with CD3 FITC and CCR7/CD197 (clone G043H7) Brilliant Violet 421™ (top) or mouse IgG2a, κ Brilliant Violet 421™ isotype control (bottom).
  • G043H7_BV421_1_101111
    Human peripheral blood lymphocytes were stained with CD3 FITC and CCR7/CD197 (clone G043H7) Brilliant Violet 421™ (top) or mouse IgG2a, κ Brilliant Violet 421™ isotype control (bottom).
  • G043H7_BV421_2_101111
Compare all formats See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
353207 25 tests £148
Check Availability


Need larger quantities of this item?
Request Bulk Quote
353208 100 tests £279
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CCR7, also known as CD197, is a chemokine receptor that binds CCL19 and CCL21. CCR7 and its ligands link innate and adaptive immunity by affecting interactions between T cells and dendritic cells and their downstream effect. Naïve T cells enter the lymph node through high endothelial venules, which express CCL21. Dendritic cells and macrophages enter the lymph node through afferent lymphatics. The encounter of T cells and dendritic cells in the T cell zone is CCR7-dependent. In addition, during immunological surveillance, B cells recirculate between B-cell-rich compartments (follicles or B cell zones) in secondary lymphoid organs, surveying for antigen. After antigen binding, B cells move to the boundary of B and T zones to interact with T-helper cells; this B cell migration is directed by CCR7 and its ligands. CCR7-positive cancer cell expression has been associated with lymph node metastasis.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Cynomolgus, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
CCR7-transfected cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Product Citations
  1. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
  2. Jiang XL, et al. 2021. Nat Commun. 12:897. PubMed
  3. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  4. Combes AJ, et al. 2022. Cell. 185:184. PubMed
  5. Ning J, et al. 2022. Cancer Immunol Immunother. 71:1863. PubMed
  6. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
  7. Asashima H, et al. 2023. Cell Rep. 42:111895. PubMed
  8. Zhong J, et al. 2023. Front Immunol. 13:1081889. PubMed
  9. Ols S, et al. 2020. Cell Reports. 30(12):3964-3971. PubMed
  10. Im KW, et al. 2023. NPJ Breast Cancer. 9:22. PubMed
  11. Preglej T, et al. 2023. Front Immunol. 14:1096096. PubMed
  12. Yan F, et al. 2023. Front Cell Infect Microbiol. 13:1152987. PubMed
  13. Eslamizar L, et al. 2021. NPJ Vaccines. 6:15. PubMed
  14. Karlsson H, et al. 2015. PLoS One. 10: 0144787. PubMed
  15. Cassotta A, et al. 2019. Nat Med. 25:1402. PubMed
  16. Spandan V Shah et al. 2018. Cell reports. 25(10):2766-2774 . PubMed
  17. Ahmed R, et al. 2020. Cell Rep. 33:108501. PubMed
  18. Mandolesi M, et al. 2021. Cell Reports Medicine. 2(4):100252. PubMed
  19. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  20. Pan YG, et al. 2021. Immunity. 54(6):1245-1256.e5. PubMed
  21. Ramaswamy A, et al. 2021. Immunity. 54(5):1083-1095.e7. PubMed
  22. Szabo PA, et al. 2021. Immunity. 54(4):797-814.e6. PubMed
  23. van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed
  24. Wallin J, et al. 2016. Nat Commun. 7:12624. PubMed
  25. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  26. Bovay A, et al. 2020. Hum Vaccin Immunother. 16:3103. PubMed
  27. Azeem W, et al. 2021. Biomedicines. 9: . PubMed
  28. Yu C, et al. 2021. Med (N Y). 2:755. PubMed
  29. Richert-Spuhler LE, et al. 2021. Cell Reports Medicine. 2(6):100322. PubMed
  30. Thompson EA, et al. 2019. Cell Rep. 28:1127. PubMed
  31. Siddiqui I et al. 2019. Immunity. 50(1):195-211 . PubMed
  32. Pais Ferreira D, et al. 2020. Immunity. 53(5):985-1000.e11. PubMed
  33. Grifoni A, et al. 2020. Cell. 181(7):1489-1501.e15.. PubMed
  34. Barcelo H, et al. 2018. Curr Protoc Cytom. 84:e35. PubMed
  35. Cassotta A, et al. 2020. J Exp Med. 217:00:00. PubMed
  36. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  37. Port JR, et al. 2020. J Virol. 94:. PubMed
  38. Bziat V, et al. 2021. Cell. . PubMed
  39. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  40. Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed
  41. Omer B, et al. 2022. Cancer Immunol Res. 10:512. PubMed
  42. Waddington KE, et al. 2020. Front Immunol. 1.51875. PubMed
  43. Halkias J, et al. 2019. J Clin Invest. 130:3562. PubMed
  44. Marcandalli J et al. 2019. Cell. 176(6):1420-1431 . PubMed
  45. Georg P, et al. 2022. Cell. 185:493. PubMed
  46. Neumann B, et al. 2015. J Leukoc Biol. 97:19. PubMed
  47. Rosato PC, et al. 2019. Nat Commun. 10:567. PubMed
  48. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  49. Gustafson CE, et al. 2020. JCI Insight. 5:. PubMed
  50. Azeem W, et al. 2020. Front Immunol. 11:438. PubMed
  51. Thyagarajan B, et al. 2018. J Immunol Methods. 463:61. PubMed
  52. Nobs SP, et al. 2017. J Exp Med. 214:3015. PubMed
  53. Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed
  54. Fu J, et al. 2021. J Clin Invest. 131:. PubMed
  55. Benner M, et al. 2020. Cell Rep. 32:108204. PubMed
  56. Darrah PA, et al. 2019. NPJ Vaccines. 4:21. PubMed
  57. Vadaq N, et al. 2022. iScience. 25:105089. PubMed
  58. Grutza R, et al. 2020. J Immunol. 204:2910. PubMed
  59. Cassotta A, et al. 2020. Eur J Immunol. . PubMed
  60. Gerna G, et al. 2015. J Gen Virol. 96:360. PubMed
RRID
AB_11203894 (BioLegend Cat. No. 353207)
AB_11203894 (BioLegend Cat. No. 353208)

Antigen Details

Structure
Chemokine receptor, G protein-coupled receptors (GPCR), seven transmembrane receptor.
Distribution

T cells, B cells, NK, dendritic cells.

Function
The chemokine receptor CCR7 plays a pivotal role in the homing of naïve T cells and regulatory T cells to secondary lymphoid organs, and the migration of dendritic cells into afferent lymphatic vessels.
Ligand/Receptor
CCL19 and CCL21.
Cell Type
B cells, Dendritic cells, NK cells, T cells
Biology Area
Immunology
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors, GPCR
Antigen References

1. Yanagihara S, et al. 1998. J. Immunol. 161:3096.
2. Charo IF, et al. 2006. N. Engl. J. Med. 354:610.
3. Reif K, et al. 2002. Nature 416:94.
4. Nakata B, et al. 2008. Oncology 74:69.
5. Brodie T. et al. 2013. Cytometry A. 6: 530-2. PubMed
6. Graves A.J. et al. 2014. Cytometry A. 7: 576–9 PubMed
7. Moncunill G. et al. 2014. Cytometry A. 12: 995-8 PubMed

Gene ID
1236 View all products for this Gene ID
UniProt
View information about CD197 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Does staining at room temperature or even at 37°C help for checking chemokine receptors expression?

Due to continuous recycling of many chemokine receptors, it may be worthwhile to consider staining at room temperature or at 37°C if the staining at lower temperature (which can potentially reduce receptor turnover) is not optimal.

Other Formats

View All CD197 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD197 (CCR7) G043H7 FC
Alexa Fluor® 488 anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 421™ anti-human CD197 (CCR7) G043H7 FC
PE anti-human CD197 (CCR7) G043H7 FC
APC/Cyanine7 anti-human CD197 (CCR7) G043H7 FC
Pacific Blue™ anti-human CD197 (CCR7) G043H7 FC
APC anti-human CD197 (CCR7) G043H7 FC
FITC anti-human CD197 (CCR7) G043H7 FC
Alexa Fluor® 647 anti-human CD197 (CCR7) G043H7 FC
PerCP/Cyanine5.5 anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 605™ anti-human CD197 (CCR7) G043H7 FC
PE/Cyanine7 anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 711™ anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 785™ anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 510™ anti-human CD197 (CCR7) G043H7 FC
Brilliant Violet 650™ anti-human CD197 (CCR7) G043H7 FC
PE/Dazzle™ 594 anti-human CD197 (CCR7) G043H7 FC
Biotin anti-human CD197 (CCR7) G043H7 FC
Purified anti-human CD197 (CCR7) (Maxpar® Ready) G043H7 FC,CyTOF®
PerCP anti-human CD197 (CCR7) G043H7 FC
Alexa Fluor® 700 anti-human CD197 (CCR7) G043H7 FC
APC/Fire™ 750 anti-human CD197 (CCR7) G043H7 FC
TotalSeq™-A0148 anti-human CD197 (CCR7) G043H7 PG
TotalSeq™-B0148 anti-human CD197 (CCR7) G043H7 PG
TotalSeq™-C0148 anti-human CD197 (CCR7) G043H7 PG
Brilliant Violet 750™ anti-human CD197 (CCR7) G043H7 FC
Ultra-LEAF™ Purified anti-human CD197 (CCR7) G043H7 FC,Block
Spark NIR™ 685 anti-human CD197 (CCR7) G043H7 FC
KIRAVIA Blue 520™ anti-human CD197 (CCR7) G043H7 FC
PE/Fire™ 640 anti-human CD197 (CCR7) G043H7 FC
Spark YG™ 581 anti-human CD197 (CCR7) G043H7 FC
APC/Fire™ 810 anti-human CD197 (CCR7) Antibody G043H7 FC
TotalSeq™-D0148 anti-human CD197 (CCR7) G043H7 PG
PE/Fire™ 810 anti-human CD197 (CCR7) Antibody G043H7 FC
PE/Cyanine5 anti-human CD197 (CCR7) G043H7 FC
Spark YG™ 593 anti-human CD197 (CCR7) G043H7 FC
PE/Fire™ 744 anti-human CD197 (CCR7) G043H7 FC
Spark Red™ 718 anti-human CD197 (CCR7) (Flexi-Fluor™) G043H7 FC
Spark Red™ 718 anti-human CD197 (CCR7) G043H7 FC
PE anti-human CD197 G043H7 FC
Spark PLUS UV395™ anti-human CD197 (CCR7) G043H7 FC
Go To Top Version: 2    Revision Date: 04/08/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account